Q1 Earnings Forecast for Rezolute Issued By HC Wainwright

Rezolute, Inc. (NASDAQ:RZLT) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Rezolute in a report issued on Friday, February 13th. HC Wainwright analyst D. Tsao expects that the company will earn ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.11) EPS and FY2030 earnings at $0.35 EPS.

RZLT has been the topic of several other research reports. Wall Street Zen lowered Rezolute from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Jefferies Financial Group restated a “buy” rating and set a $20.00 price target on shares of Rezolute in a research note on Friday, December 5th. Maxim Group set a $4.00 price target on Rezolute in a research report on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rezolute in a research note on Thursday, January 22nd. Finally, Citigroup lowered shares of Rezolute from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 11th. Five equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Rezolute currently has an average rating of “Hold” and an average price target of $7.63.

Rezolute Price Performance

Shares of NASDAQ:RZLT opened at $3.63 on Monday. Rezolute has a 12 month low of $1.07 and a 12 month high of $11.46. The firm has a market capitalization of $347.39 million, a P/E ratio of -3.90 and a beta of 0.46. The company’s fifty day moving average price is $2.88 and its 200 day moving average price is $6.50.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings data on Thursday, February 12th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.06).

Institutional Investors Weigh In On Rezolute

A number of institutional investors have recently added to or reduced their stakes in the business. New York State Common Retirement Fund raised its stake in shares of Rezolute by 5.6% during the 3rd quarter. New York State Common Retirement Fund now owns 24,600 shares of the company’s stock worth $231,000 after buying an additional 1,300 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Rezolute by 5.0% during the third quarter. JPMorgan Chase & Co. now owns 33,201 shares of the company’s stock worth $312,000 after acquiring an additional 1,567 shares during the period. Pale Fire Capital SE raised its position in Rezolute by 4.2% in the second quarter. Pale Fire Capital SE now owns 49,122 shares of the company’s stock worth $219,000 after acquiring an additional 2,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Rezolute by 5.5% in the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,659 shares of the company’s stock worth $363,000 after acquiring an additional 2,014 shares in the last quarter. Finally, Huntleigh Advisors Inc. lifted its holdings in Rezolute by 16.7% in the third quarter. Huntleigh Advisors Inc. now owns 17,500 shares of the company’s stock valued at $164,000 after acquiring an additional 2,500 shares during the period. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Daron Evans acquired 40,000 shares of the company’s stock in a transaction on Monday, December 15th. The shares were bought at an average cost of $1.77 per share, with a total value of $70,800.00. Following the purchase, the chief financial officer owned 415,900 shares of the company’s stock, valued at $736,143. This represents a 10.64% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Nevan C. Elam acquired 32,000 shares of the business’s stock in a transaction on Monday, December 15th. The shares were purchased at an average price of $1.59 per share, with a total value of $50,880.00. Following the transaction, the chief executive officer owned 641,119 shares in the company, valued at $1,019,379.21. The trade was a 5.25% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 89,100 shares of company stock worth $150,232. 14.78% of the stock is currently owned by insiders.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.